Literature DB >> 10328232

Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.

L Peduto Eberl1, L Guillou, E Saraga, M Schröter, L E French, J Tschopp, L Juillerat-Jeanneret.   

Abstract

CD95/APO-1 ligand (FasL) is implicated in the maintenance of immune privileged sites by inducing apoptosis of activated infiltrating T lymphocytes. Therefore, progressive tumors might express high levels of FasL and develop as immune privileged sites. In this study, we investigated the expression of FasL and CD95/APO-1 (Fas, the FasL-receptor) in vitro in rat adenocarcinoma cell lines and the localization in situ in normal human kidney and colon and in their adenocarcinomas. The rat cell line PROb (a progressive tumor in vivo) expressed a higher level of FasL than the sister cell line REGb (a regressive tumor in vivo), as detected by flow cytometry. The 2 cell lines expressed the same level of Fas, but were resistant to FasL-induced apoptosis. In human tissue, both kidney and colon extracts expressed FasL by Western blot. Further investigations, using immunohistochemical staining of paraffin sections, showed that normal colon mucosa expressed Fas and FasL in crypt epithelial cells in the subnuclear compartment. Normal kidney showed Fas and FasL labeling mostly restricted to epithelial cells of proximal tubules and Henlé's loop, showing that this expression is not uniform throughout the organ. Smooth-muscle cells of muscularis propria and blood vessels in and around the tumors were also intensely but more uniformly labeled. In colon-cancer cells, FasL expression remained strong, whereas Fas expression was significantly reduced. A similar reduction in Fas expression was noted in renal-cancer cells. Tumor-infiltrating immune cells of the macrophage lineage do not express FasL. Our results show that smooth-muscle cells of muscularis propria and blood vessels are able to express FasL and to a slight extent Fas. In normal epithelial cells of colon and kidney, Fas and FasL are often co-expressed. The reduced expression of Fas in corresponding cancer cells in combination with the ability to express FasL might facilitate immune escape.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328232     DOI: 10.1002/(sici)1097-0215(19990531)81:5<772::aid-ijc18>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Association of FAS A-670G Polymorphism and Risk of Uterine Leiomyoma in a Southeast Iranian Population.

Authors:  Abbas Mohammadpour-Gharehbagh; Saeedeh Salimi; Farshid Keshavarzi; Sepideh Zakerian; Mojtaba Sajadian; Mojgan Mokhtari
Journal:  Rep Biochem Mol Biol       Date:  2016-10

2.  Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas.

Authors:  Z Y Li; S Q Zou
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

3.  Polymorphonuclear Neutrophils and Tumors: Friend or Foe?

Authors:  Izabela Szulc-Kielbik; Magdalena Klink
Journal:  Exp Suppl       Date:  2022

4.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

5.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 6.  Immune-epithelial crosstalk at the intestinal surface.

Authors:  Nadine Wittkopf; Markus F Neurath; Christoph Becker
Journal:  J Gastroenterol       Date:  2014-01-28       Impact factor: 7.527

7.  Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.

Authors:  L Peduto Eberl; R Bovey; L Juillerat-Jeanneret
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

8.  Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.

Authors:  H Yao; E Song; J Chen; P Hamar
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

9.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.

Authors:  J D Kelly; J Dai; P Eschwege; J S Goldberg; B P Duggan; K E Williamson; N H Bander; D M Nanus
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.